# reload+after+2024-01-23 19:47:22.487865
address1§301 Binney Street
address2§3rd Floor
city§Cambridge
state§MA
zip§02142
country§United States
phone§857 259 3860
website§https://scholarrock.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§114
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jay T. Backstrom M.D., M.P.H.', 'age': 68, 'title': 'President, CEO & Director', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 686492, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Edward H. Myles MBA', 'age': 51, 'title': 'CFO, COO & Treasurer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 668485, 'exercisedValue': 0, 'unexercisedValue': 52199}, {'maxAge': 1, 'name': 'Ms. Junlin  Ho J.D.', 'age': 44, 'title': 'General Counsel & Corporate Secretary', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 563729, 'exercisedValue': 0, 'unexercisedValue': 112564}, {'maxAge': 1, 'name': 'Ms. Catherine  Hu', 'title': 'Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Caryn  Parlavecchio', 'age': 51, 'title': 'Chief Human Resources Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lisa Amaya Price', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Erin  Moore', 'age': 48, 'title': 'Senior Vice President of Finance', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan  Iarrobino', 'title': 'Senior Vice President of Clinical Development & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jing L. Marantz M.B.A., M.D., Ph.D.', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tracey M. Sacco M.B.A.', 'age': 47, 'title': 'Chief Commercial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.736
priceToSalesTrailing12Months§Infinity
currency§USD
dateShortInterest§1702598400
forwardEps§-1.91
exchange§NMS
quoteType§EQUITY
shortName§Scholar Rock Holding Corporatio
longName§Scholar Rock Holding Corporation
firstTradeDateEpochUtc§1527255000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d4172360-ba22-3374-b294-8dd0e33412b6
gmtOffSetMilliseconds§-18000000
targetHighPrice§30.0
targetLowPrice§20.0
targetMeanPrice§25.71
targetMedianPrice§28.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§8.179
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
